Clinuvel Pharmaceuticals Limited Share Price
Stocks
CUV
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.27 AUD | -1.72% |
|
+0.20% | -17.58% |
| 02/07 | Clinuvel Pharmaceuticals Extends CEO Philippe Wolgen's Term of Employment | MT |
| 16/06 | Clinuvel Pharmaceuticals Advances US Listing Plan With SEC Filing for Nasdaq ADS Upgrade | MT |
| Market Cap | 52Cr 36Cr 32Cr 29Cr 27Cr 51Cr 3.44TCr 347.25Cr 136.37Cr 1.69TCr 135.25Cr 132.31Cr 5.82TCr | P/E 2026 * |
14.4x | P/E 2027 * | 13.5x |
|---|---|---|---|---|---|
| Enterprise Value | 26Cr 18Cr 16Cr 15Cr 14Cr 26Cr 1.75TCr 177.15Cr 70Cr 863.4Cr 69Cr 67Cr 2.97TCr | EV / Sales 2026 * |
2.66x | EV / Sales 2027 * | 2.2x |
| Free-Float |
83.79% | Yield 2026 * |
0.6% | Yield 2027 * | 0.78% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | -1.72% | ||
| 1 week | +0.20% | ||
| Current month | -0.10% | ||
| 1 month | +17.78% | ||
| 3 months | +12.98% | ||
| 6 months | -18.75% | ||
| Current year | -17.58% |
| 1 week | 10 |  | 10.58 |
| 1 month | 8.8 | | 10.74 |
| Current year | 8.35 | | 13.48 |
| 1 year | 8.35 | | 14 |
| 3 years | 8.35 | | 21.45 |
| 5 years | 8.35 | | 44.67 |
| 10 years | 4.6 | | 45.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 03/24/03 | Buy | Director | 8,333 | 0.0166% | ||
| 27/23/27 | Fiscal year | Chief Executive Officer | 3,01,125 | 0.6094% | ||
| 27/23/27 | Expiration | Chief Executive Officer | 15,13,750 | 3.0636% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.72% | +0.20% | -1.91% | -41.08% | 36Cr | |
| -0.51% | +1.57% | +18.72% | -5.52% | 6.76TCr | |
| -5.16% | -8.63% | +37.37% | +202.27% | 5.16TCr | |
| -2.10% | +0.89% | -49.30% | -53.47% | 4.09TCr | |
| +5.28% | +39.50% | +39.50% | +39.50% | 4.3TCr | |
| -10.83% | -14.41% | +99.15% | -44.54% | 2.71TCr | |
| +0.12% | -7.85% | +47.16% | -29.27% | 2.94TCr | |
| -1.53% | -0.13% | +65.92% | +88.58% | 2.33TCr | |
| +3.88% | +2.16% | +11.78% | +201.51% | 1.99TCr | |
| -4.75% | +11.27% | +85.63% | +394.76% | 1.68TCr | |
| Average | -1.73% | -1.41% | +35.40% | +75.27% | 3.2TCr | |
| Weighted average by Cap. | -1.53% | -2.15% | +31.74% | +63.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.95Cr 6.92Cr 6.05Cr 5.58Cr 5.16Cr 9.78Cr 659.8Cr 67Cr 26Cr 325.04Cr 26Cr 25Cr 1.12TCr | 11Cr 7.33Cr 6.41Cr 5.91Cr 5.46Cr 10Cr 698.91Cr 71Cr 28Cr 344.3Cr 28Cr 27Cr 1.18TCr |
| Net income | 3.6Cr 2.5Cr 2.19Cr 2.02Cr 1.86Cr 3.54Cr 238.6Cr 24Cr 9.47Cr 117.54Cr 9.39Cr 9.19Cr 404.08Cr | 3.82Cr 2.66Cr 2.32Cr 2.14Cr 1.98Cr 3.76Cr 253.41Cr 26Cr 10Cr 124.84Cr 9.98Cr 9.76Cr 429.17Cr |
| Net Debt | -25Cr -18Cr -15Cr -14Cr -13Cr -25Cr -1.68TCr -170.11Cr -67Cr -829.09Cr -66Cr -65Cr -2.85TCr | -29Cr -20Cr -17Cr -16Cr -15Cr -28Cr -1.9TCr -191.79Cr -75Cr -934.77Cr -75Cr -73Cr -3.21TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/26/10 | A$10.27 | -1.72% | 1,09,586 |
| 09/26/09 | A$10.45 | +1.65% | 1,77,685 |
| 08/26/08 | A$10.28 | -0.10% | 1,44,738 |
| 07/26/07 | A$10.29 | +0.78% | 1,20,441 |
| 06/26/06 | A$10.21 | -0.39% | 66,784 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
